STUDY SHOWS PARKINSON'S TREATMENT TO BE EFFECTIVE, SAFE

A A

Schwarz Pharma has reported that Phase III trial results show that its Rotigotine transdermal system, the Neupro patch, is effective and safe in combination with stable levodopa treatment in patients with advanced Parkinson's disease.

The patch is applied to the skin once a day and provides rotigotine continuously to the body for 24 hours. The response of patients with advanced stage of Parkinson's disease showed statistically significant and clinically relevant reduction in off-time (when patients suffer from dyskinesia or uncontrolled movements) when compared to placebo-treated patients. Results of the study showed that both primary endpoints for the U.S. and Europe were achieved and the product appeared to be well-tolerated.